EDUCATION
Pharm.D. (Pharmacy) 2000, University of Arizona, College of Pharmacy
M.S. (Pharmacoeconomics, Policy, and Health Outcomes Research) 2002, University of Arizona
PROFESSIONAL LICENSURE
Pharmacy, Arizona (#S12508), 2000-Present
Pharmacy, Indiana (#26020687A), 2002-2007
EMPLOYMENT
|
3/10 - Present |
Adjunct Associate Scientist, Lovelace Respiratory Research Institute, Albuquerque, NM |
|
2009 - Present |
Principal Research Scientist, Premier Research Services, Premier, Inc., Healthcare Informatics, Charlotte, NC |
|
2006 - 2009 |
Senior Research Scientist, Premier Research Services, Premier, Inc., Healthcare Informatics, Charlotte, NC |
|
2006 |
Associate Outcomes Research Consultant, US Outcomes Research, Critical Care, Eli Lilly and Company, Indianapolis, IN |
|
2003 - 2006 |
Senior Outcomes Research Associate, US Outcomes Research, Critical Care, Eli Lilly and Company, Indianapolis, IN |
|
2002 - 2003 |
Senior Outcomes Research Associate, US Outcomes Research, Neuroscience, Eli Lilly and Company, Indianapolis, IN |
|
2002 - 2006 |
Part-time Pharmacist, CVS/Pharmacy, Indianapolis/Zionsville, IN |
|
2000 - 2002 |
Health Outcomes Research Fellow, Global Economic Affairs, Eli Lilly and Company, Indianapolis, IN |
|
2000 - 2001 |
Pharmacist, Jones United Drug Company, Tucson, AZ |
|
2000 - 2001 |
Clinical Assistant I, Pharmacy Practice, University of Arizona College of Pharmacy, Tucson, AZ |
|
1999 - 2000 |
Pharmacy Intern, Fry’s Food and Drug, Tucson, AZ |
|
1998 - 2000 |
Assistant, History of Pharmacy Museum, University of Arizona College of Pharmacy, Tucson, AZ |
|
1998 - 2000 |
Research Assistant, Pharmacy Practice, University of Arizona College of Pharmacy, Tucson, AZ |
|
1997 |
Summer Pharmacy Intern, Wal-Mart, Green Valley, AZ |
|
1995 - 1997 |
Research Laboratory Assistant, Pharmacology/Toxicology, University of Arizona College of Pharmacy, Tucson, AZ |
AWARDS AND RECOGNITION
Golden Key National Honor Society, 1996
Glaxo Wellcome Pride in Pharmacy Scholarship, 1997
American Institute of the History of Pharmacy Student Recognition, 1997
Rho Chi Recognition, 1997
Charles M. Nielsen Scholarship, 1997, 1998
Phi Lambda Sigma (FLS) Pharmacy Leadership Society, 1998
Albert L. Picchioni Student Leadership Scholarship, 1998
Wal-Mart Scholarship, 1998
Spectrum Leadership Honorary, 1998
Who’s Who Among Students in American Universities & Colleges, 1998
Omicron Delta Kappa (ODK) National Leadership Honor Society, 1999
Andrew P. Martin Memorial Scholarship, 1999
Edwin W. Carroll Scholarship, 1999
PharmD Class of 2000 President, 2000
Phi Lambda Sigma–Glaxo Wellcome–AFPE Graduate Scholarship, 2000
University of Arizona Foundation Outstanding Senior Award, 2000
Phi Lambda Sigma Senior Leadership Award, 2000
Pfizer Outstanding Leader Award, 2000
Best Contributed Poster Award, ISPOR Annual Research Meeting, 2006
Premier Performance Excellence Team Award, 2009
PUBLICATIONS
-
Ernst, F. R. and A. J. Grizzle: Drug-Related Morbidity and Mortality: Updating the Cost-of-Illness Model. J. Am. Pharm. Assoc. 41(2): 192-199, 2001.
-
Delate, T., F. R. Ernst and S. J. Coons: The Role of Health-Related Quality-of-Life Data in Pharmacy Benefit Decisions. Pharmacy & Therapeutics (P&T) 27(1): 24, 30-32, 2002.
-
Ascher-Svanum, H., B. Zhu, D. Faries and F. R. Ernst: A Comparison of Olanzapine and Risperidone on the Risk of Psychiatric Hospitalization in the Naturalistic Treatment of Patients with Schizophrenia. Ann. Gen. Hosp. Psychiatry 3(1): 11, 2004.
-
Ernst, F. R., S. Viswanathan, G. Vedarajan, B. Kohli, J. Reynolds and B. Bates: The Challenges of Identification of Severe Sepsis in Administrative Data and Feasibility of an Alternative Method. Adv. Sepsis 5(1): 11-18, 2005.
-
Alexander, S. L. and F. R. Ernst: Use of Drotrecogin Alfa (Activated) in Older Patients with Severe Sepsis. Pharmacotherapy 26(4): 533-538, 2006.
-
Ascher-Svanum, H., B. Zhu, D. Faries, F. R. Ernst, M. Swartz and J. Swanson: Medication Adherence and Long-Term Functional Outcomes in the Treatment of Schizophrenia in Usual Care. J. Clin. Psych. 67(3): 453-460, 2006. (Star Reprint)
-
Durthaler, J. M. and F. R. Ernst: An Evidence-Based Disease Management Approach to Evaluating the Use of Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis. Am. J. Health Syst. Pharm. 63(15): 1453-1460, 2006.
-
Ernst, F. R., W. N. Malatestinic and W. T. Linde-Zwirble: Evaluating the Clinical and Financial Impact of Severe Sepsis with Medicare or Other Administrative Hospital Data. Am. J. Health Syst. Pharm. 63(6): 575-581, 2006.
-
Ascher-Svanum, H., B. Zhu, F. R. Ernst, D. E. Faries, J. E. Jacobson and C. C. Doebbeling: The 3-Year Clinical and Functional Course of Schizophrenia Among Patients with and without Diabetes at Study Entry. Prim. Care Companion J. Clin. Psychiatry 9(2): 122-128, 2007.
-
Ernst, F. R., J. A. Johnston, S. Pulgar, J. He, D. E. Ball, J. K. Young and L. M. Cooper: Timing of Drotrecogin Alfa (Activated) Initiation in Treatment of Severe Sepsis: A Database Cohort Study of Hospital Mortality, Length of Stay, and Costs. Curr. Med. Res. Opin. 23(1): 235-244, 2007.
-
Ernst, F. R., H. Levy and R. L. Qualy: Simplified Pharmacoeconomics of Critical Care and Severe Sepsis. J. Intensive Care Med. 22(5): 283-293, 2007.
-
Durthaler, J. M., F. R. Ernst and J. A. Johnston: Managing Severe Sepsis: A National Survey of Current Practices. Am. J. Health Syst. Pharm. 66(1): 45-53, 2009.
-
Burke, T. A., T. Wisniewski and F. R. Ernst: Resource Utilization and Costs of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Moderately or Highly Emetogenic Chemotherapy Administered in the US Outpatient Hospital Setting. Supportive Care Cancer [Epub ahead of print, doi:10.1007/s00520-009-0797-x], 2010.
-
Craver, C. W., M. Tarallo, C. S. Roberts, C. M. Blanchette and F. R. Ernst: Cost and Outcomes Associated with Fluconazole as First-Line Therapy for Invasive Candidiasis. Clin. Ther. (in press).